Feb 5- A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. They closed up $2.00, or 19.7 percent, at $12.13 on the Nasdaq. District Judge Renée Marie Bumb in Camden, New Jersey said Allergan's proposed generic infringed two of the three Supernus...» Read More
Genzyme may make orphan drugs, but this company is a lot closer to Daddy Warbucks.
For quite some time now the major American pharmaceutical companies have been benefitting from the foreign exchange rate. But given the recent strength in the greenback, Deutsche Bank analyst Barbara Ryan says the sector may not be able to rely on forex for very much longer.
Cramer offers up five reasons why this sector is the best one to own through the fall. Plus, the top stocks in the group.
I wanted to be sure and call attention to the fact that PFE is no longer a teenager. Shares of the Dow component have broken above $20. If the stock can stay there at 4 p.m. that'll be the first time Pfizer's closed above that level since May 21st.
Analysts are pretty much in agreement that Swiss drugmaker Roche is gonna have to pony up more than the 89 bucks it has already offered for the rest of Genentech it doesn't currently own.
Following are the week's biggest winners and losers, including a couple of well-known household goods companies, a luxury brand and a couple of techs thrown in for good measure.
The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.
Following are Thursday's biggest winners and losers. Even with today's rough market, there were a number of pops, such as an internet florist, a Canadian fast food chain and a certain star athlete making the move to the Big Apple.
A week after Bristol-Myers Squibb made its move for ImClone Systems, one of the people who made the biotech infamous could be getting out of the clink.
In the latest move in the big pharma restructuring/outsourcing trend, Eli Lilly announced this morning that it's selling a lab site in its home state of Indiana to the contract research organization Covance.
We reporters who cover biopharma are inundated with story pitches from companies and PR folks. Most of them go immediately into the electronic trash bin. But I couldn't let this one go so fast
Just before the opening bell this morning ImClone Systems put out a clearly Carl Icahn-inspired press release regarding last week's $60-a-share buyout offer from Bristol-Myers Squibb.
Biotechnology company ImClone Systems said on Monday that a $60-per-share takeover bid from partner Bristol-Myers Squibb was too low, but it would hire financial advisers to help it study the unsolicited offer.
Health care stocks have been the stealth performers, and they will likely continue to outperform because of steady earnings, a favorable macro environment and cheap valuations, says Merrill Lynch's Brian Belski.
This coffee giant looks a lot like McDonald's before it turned up, Cramer says.
What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.
Shares in Irish drugmaker Elan dived more than 50 percent to their lowest level since 2005 on Friday as a second product setback in a week shattered confidence in its line-up of biotech medicines.
Novo Nordisk's diabetes drug might just send this stock much, much higher.
Biogen Idec and Elan notified regulators of two confirmed cases of a potentially deadly brain disease in multiple sclerosis (MS) patients being treated with Tysabri.
Bristol-Myers Squibb's proposal to buy ImClone Systems at $4.5 billion brings back memories of the Martha Stewart scandal that went beyond financial news headlines and made ImClone a household name.